Fritextsökning
Innehållstyper
-
FDA approves first non-opioid pain reliever in over 20 years
For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.
-
LINK Medical recruits Swedish CEO
The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.
-
Moderna develops mRNA vaccine against norovirus
A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...
-
Björn Arvidsson will lead research and innovation in Region Uppsala
The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.
-
Pneumatics Makes a Technological Leap with Piezo
The first high-precision proportional valve terminal VTEP opens up new application areas
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thro...
-
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...
-
Quality Assurance for the Highest Medical Standards
Metrology Solutions for Medical Components.
-
Ingrid Lönnstedt: What does the p-value mean?
The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significa...
-
How the Foreign Office will promote Swedish life science exports
The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...
-
“I am driven by the desire to develop a product that can be sold worldwide”
Ranked number one in the world by the WHO in diarrhoea research and soon in phase III studies for its vaccine candidate – Scandinavian Biopharma is rushing forw...
-
“Don’t postpone the transition to IVDR”
Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...
-
Automated nitrogen analysis reduces costs per sample
N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo
-
Rise and Scantox cease conducting animal testing in Stockholm
Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...
-
GSK acquires oncology research company
GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.
-
Festo liquid dispensing: going fast and slow
Dispensing liquid with Festo equipment developed for automation can really be adapted to your needs
-
The key to successful collaboration between industry and academia
Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?
-
Spatial Biology Studies in Lung Tissue using Spectral Microscopy
Spectral imaging with the ZEISS LSM 980 laser scanning confocal enables more complex studies of cell-cell interactions and locations in immunology research.
-
Novo Nordisk to invest billions in new quality control lab
Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.
-
Novo Nordisk establishes new factory in Denmark
Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.
-
Ready-to-install solutions for the lab-on-a-chip
Design for manufacturing lab-on-a-chip devices Reducing time-to-market together
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.